ArticleOncoTargets and therapy2023

Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer.

Yan Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.